Foghorn Therapeutics
Zhen Y. is a finance and strategic planning expert currently serving as the Director of Strategic Finance at Foghorn Therapeutics Inc. since May 2024. Previously, Zhen held the position of Associate Director of Strategic Finance at L.E.K. Consulting from August 2022 to April 2024, specializing in corporate strategy and due diligence for the pharmaceutical and biotechnology sectors. Zhen’s experience also includes a role as a Life Sciences Consultant while pursuing an MBA at MIT Sloan School of Management from August 2020 to May 2022. Earlier in Zhen’s career, a significant tenure at Amgen from July 2016 to August 2020 involved managing R&D finance, focusing on investment prioritization and clinical trial financial planning, alongside positions in corporate finance. Zhen holds an MBA from MIT Sloan School of Management and a BBA in Finance and Biology from Emory University.
This person is not in any teams
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.